Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Aude Roborel De Climens"'
Autor:
Anna Cardellino, Manasee Shah, Jennifer Hanlon, Kimberly Kelly, Alexandra Martin, Aude Roborel de Climens, Sara Taiyari, Alexander Stojadinovic
Publikováno v:
Frontiers in Psychology, Vol 14 (2023)
IntroductionAdvanced or metastatic non-small cell lung cancer (NSCLC) is associated with significant symptom burden. It is important to understand the impact of these disease-and treatment-related symptoms on patients’ daily lives and explore from
Externí odkaz:
https://doaj.org/article/0ab1f00694454f7f91a498d427b2e2ec
Autor:
Jean-François Yale, Aude Roborel de Climens, Naresh Aggarwal, Terry Dex, Hertzel C. Gerstein, Stewart Harris, Irene Hramiak, John Stewart, Lawrence A. Leiter
Publikováno v:
Diabetes Therapy. 14:377-386
For people with type 2 diabetes mellitus who do not achieve glycated hemoglobin A1C targets after treatment with basal insulin therapies, additional therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) may be required. One option is to
Autor:
NIAZ KHAN, AMIR TIROSH, ANIL BHANSALI, HERNANDO VARGAS-URICOECHEA, STEWART B. HARRIS, AUDE ROBOREL DE CLIMENS, MARIA AILEEN N. MABUNAY, MATHIEU COUDERT, VALERIE PILORGET, GAGIK R. GALSTYAN
Publikováno v:
Diabetes. 71
Patients' satisfaction is a key determinant of treatment adherence and persistence, for optimal management of T2D. ATOS, a 12-month prospective observational study conducted in Asia, Middle East, North Africa, Latin America, and Eastern Europe, showe
Autor:
Aude Roborel de Climens, Carla Dias Barbosa, Catherine Brun-Strang, Ronald Buggage, Béatrice Tugaut
Publikováno v:
Ophthalmic Genetics. 42:150-160
Background: Stargardt disease (STGD), a rare, inherited macular degeneration most commonly affecting children and young adults, is a rapidly progressive disease leading to severe central vision los...
Publikováno v:
Diabetes Therapy
Introduction Type 2 diabetes mellitus (T2DM) requires long-term treatment to achieve and maintain glycaemic control; however, up to 50% of people with T2DM discontinue treatment by 1 year. It is therefore important to understand the patient perspecti
Autor:
Grégory Bigot, Zsolt Bosnyak, Lori Berard, Emma G. Wilmot, Luis Eduardo Calliari, Daniela Bruttomesso, F. Javier Ampudia-Blasco, Anne L. Peters, Jochen Seufert, Dubravka Jurišić-Eržen, Eric Renard, Aude Roborel de Climens, Kelly L. Close
Publikováno v:
Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, Wiley, 2021, 23 (8), pp.1892-1901. ⟨10.1111/dom.14416⟩
Diabetes, Obesity and Metabolism, 2021, 23 (8), pp.1892-1901. ⟨10.1111/dom.14416⟩
Diabetes, Obesity and Metabolism, Wiley, 2021, 23 (8), pp.1892-1901. ⟨10.1111/dom.14416⟩
Diabetes, Obesity and Metabolism, 2021, 23 (8), pp.1892-1901. ⟨10.1111/dom.14416⟩
International audience; Aims: This secondary analysis of the SAGE study aimed to evaluate the association between glycaemic control and patient-reported outcomes (PROs), in adults with type 1 diabetes (T1DM) across different age groups and regions.Ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1763bf708cc1f8afe57783b01384ef3f
https://hal.archives-ouvertes.fr/hal-03218691
https://hal.archives-ouvertes.fr/hal-03218691
Autor:
Amy Findley, My-Liên Nguyên-Pascal, Aude Roborel de Climens, Matthew Reaney, Catherine Brun-Strang, Adam Gater, Kate Burrows
Publikováno v:
Drug Safety
Introduction Individualised benefit–harm assessments can help identify patient-perceived benefits and harms of a treatment, and associated trade-offs that may influence patients’ willingness to use a treatment. This research presents the first us
Autor:
Elías Delgado, Aude Roborel de Climens, Luiza Popescu, Krzysztof Strojek, Hans A. Frandsen, George Dimitriadis, Bernd Schultes, Melanie J. Davies, Mireille Bonnemaire, Arnaud Dauchy, David Russell-Jones
Publikováno v:
Diabetes, Obesity & Metabolism
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
instname
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
instname
Aim To compare the efficacy and safety of self‐ versus physician‐managed titration of insulin glargine 300 U/mL (Gla‐300) in people with inadequately controlled type 2 diabetes. Methods Take Control (EudraCT number: 2015‐001626‐42) was a 24
Autor:
Jukka Westerbacka, Luigi Meneghini, Stewart B. Harris, Aude Roborel De Climens, Frank J. Snoek, Felipe Lauand, Kamlesh Khunti
Publikováno v:
Diabetes. 69
BI analogs can help optimize glycemic control in people with T2D, but the patients’ satisfaction is key for acceptance and treatment adherence. ACHIEVE, REACH, and REGAIN were open-label real-world studies comparing Gla-300 with standard of care BI
Publikováno v:
Diabetes. 69
T2D is a chronic condition that requires long-term treatment to achieve and maintain glycemic control. However, up to 50% of people with T2D discontinue treatment by 1 year. To better understand why this occurs, an online questionnaire was presented